Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Trainer

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Reviews in Endocrine & Metabolic Disorders|March 16, 2013
The use of mass spectrometry to improve the diagnosis and the management of the HPA axisPhillip J Monaghan, Brian G Keevil, Peter J Trainer
European Journal of Endocrinology|February 3, 2006
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegalyAna Pokrajac, Andrew G Claridge, S K Abdul Shakoor, et al.
Clinical Endocrinology|March 24, 2009
Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testingIlias Perogamvros, Laura J Owen, Brian G Keevil, et al.
Clinical Endocrinology|May 15, 2009
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegalyPeter J Trainer, Shereen Ezzat, Gwyn A D'Souza, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disordersAnnice Mukherjee, John P Monson, Peter J Jönsson, et al.
Clinical Endocrinology|April 12, 2013
Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonistsTrevor A Howlett, Debbie Willis, Gillian Walker, et al.
The Journal of Clinical Endocrinology and Metabolism|January 29, 2009
Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegalyAngela N Paisley, Ashley S Izzard, Islay Gemmell, et al.
Annals of Clinical Biochemistry|August 5, 2011
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyraponePhillip J Monaghan, Laura J Owen, Peter J Trainer, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2005
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaireSusannah V Rowles, L Prieto, X Badia, et al.
Neurosurgery|September 28, 2010
Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curvePaul Leach, Ahmed H Abou-Zeid, Tara Kearney, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Reviews in Endocrine & Metabolic Disorders|March 16, 2013
The use of mass spectrometry to improve the diagnosis and the management of the HPA axisPhillip J Monaghan, Brian G Keevil, Peter J Trainer
European Journal of Endocrinology|February 3, 2006
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegalyAna Pokrajac, Andrew G Claridge, S K Abdul Shakoor, et al.
Clinical Endocrinology|March 24, 2009
Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testingIlias Perogamvros, Laura J Owen, Brian G Keevil, et al.
Clinical Endocrinology|May 15, 2009
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegalyPeter J Trainer, Shereen Ezzat, Gwyn A D'Souza, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disordersAnnice Mukherjee, John P Monson, Peter J Jönsson, et al.
Clinical Endocrinology|April 12, 2013
Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonistsTrevor A Howlett, Debbie Willis, Gillian Walker, et al.
The Journal of Clinical Endocrinology and Metabolism|January 29, 2009
Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegalyAngela N Paisley, Ashley S Izzard, Islay Gemmell, et al.
Annals of Clinical Biochemistry|August 5, 2011
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyraponePhillip J Monaghan, Laura J Owen, Peter J Trainer, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2005
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaireSusannah V Rowles, L Prieto, X Badia, et al.
Neurosurgery|September 28, 2010
Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curvePaul Leach, Ahmed H Abou-Zeid, Tara Kearney, et al.
Pageof 6